Drug Profile
LY 2624803
Alternative Names: HY 10275; LY2624803Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Sleep disorder therapies
- Mechanism of Action Histamine H1 receptor agonists; Histamine H1 receptor antagonists; Serotonin 2A receptor antagonists; Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Insomnia
Most Recent Events
- 24 Jan 2011 Discontinued - Phase-I for Insomnia in United Kingdom (PO)
- 24 Jan 2011 Discontinued - Phase-II for Insomnia in USA (PO)
- 14 May 2010 Eli Lilly completes a phase I trial in Insomnia in USA